VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Completed · Phase 1/Phase 2
Conditions studied: Fallopian Tube Cancer, Malignant Tumor of Peritoneum, Recurrent Ovarian Epithelial Cancer
In brief
This phase I/II trial is studying the side effects and best dose of VEGF Trap when given together with docetaxel and to see how well they work in treating patients with persistent or recurrent ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving VEGF Trap together with docetaxel may kill more tumor cells
Key facts
- Study ID
- NCT00436501
- Run by
- National Cancer Institute (NCI)
- People needed
- 58
- Starts
- 2007-01-01
- Expected to finish
- 2012-11-01
- Last updated by the study team
- 2019-02-26
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- M D Anderson Cancer Center — Houston, Texas, United States
- University of Virginia Health System — Charlottesville, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.